PRiME Lab Hero

PRiME Lab

Peptide Regulators for Ion Channels and Membrane Protein Exploration

From Peptides to Medicine: Discovering Nature's Keys to Ion Channels and Membrane Receptors

"Discovering Nature's Keys
to Ion Channels
and Membrane Receptors"

Beyond the Barrier of Pain,
Restoring the Experience of a Whole World

Understanding membrane proteins at the atomic level is the critical first step toward transforming patients' lives.

We discover nature's modulators and design novel peptide/protein therapeutics to restore everyday life for those suffering from pain and neurological disorders.

Our Research Focus

Target Discovery

Ion Channels & GPCRs

  • Structural mechanisms
  • Key functional motifs
  • Protein-protein interactions
  • Intra/extracellular regulators

Modulator Development

Peptide & Protein Engineering

  • Nature-inspired design
  • Structure-activity relationships
  • Selectivity optimization
  • Novel modality therapeutics

Translation to Therapy

From Molecules to Medicine

  • Pharmacological validation
  • Pain & neurological applications
  • Preclinical development
  • Clinical translation

Key Research Areas

Membrane Protein Mechanisms

Decoding Molecular Machinery

  • Ion channel gating & modulation
  • GPCR signaling & trafficking
  • Structural dynamics & conformational states
  • Disease-relevant mechanisms

Peptide & Protein Modulators

Nature-Inspired Molecular Tools

  • Endogenous regulatory peptides
  • Toxin-derived scaffolds
  • Engineered protein modulators
  • Allosteric & orthosteric regulation

Structure-Function Analysis

Atomic-Level Understanding

  • Critical binding motifs
  • Protein-protein interactions
  • Intracellular/extracellular regulators
  • Structure-based drug design

Therapeutic Development

New Modality Medicines

  • Peptide drug optimization
  • Selectivity & efficacy enhancement
  • Pain & neurological therapeutics
  • Translational pharmacology

Patient-Derived iPSC Modeling

Disease Mechanism & Drug Testing

  • Patient-derived iPSC reprogramming
  • Neuronal differentiation & phenotyping
  • Disease-specific cellular models
  • Drug response profiling

AI-Driven Peptide Design

Computational Drug Discovery

  • Deep learning structure prediction
  • Molecular dynamics simulation
  • Binding affinity optimization
  • De novo peptide generation

Our Target Proteins

Ion Channels

TRPV1 TRPA1 TRPM8 Nav1.7 Nav1.8 Kv channels

G Protein-Coupled Receptors

GLP-1 Receptor GIP Receptor Opioid Receptors Pain-related GPCRs

Publications

High-impact research in ion channel biology and peptide therapeutics

Loading publications...

People

Building a world-class research team

Yong Ho Kim, Ph.D.

Principal Investigator

Associate Professor, Gachon University College of Medicine (2017–Present)
CEO & Founder, RudaCure Co., Ltd. (2018–Present)

Research Interests

  • Ion channel and GPCR structure-function analysis
  • Peptide and protein modulators of membrane receptors
  • Patient-derived iPSC disease modeling
  • Mechanisms of pain and sensory disorders
  • Translational therapeutics development

Contact

Email: euro16@gachon.ac.kr

Join Our Growing Team

We are actively recruiting talented graduate students, postdocs, and research scientists to build a world-class research team. If you are passionate about ion channel biology, peptide therapeutics, and translational research, we invite you to be part of our journey toward scientific excellence.

We are currently recruiting! For more information, please visit our Join Us section or contact us directly.

News & Updates

Latest achievements and announcements from PRiME Lab

2025.12

Incheon Metropolitan City Award for Bio-Industry Development

Prof. Yong Ho Kim received the Incheon Metropolitan City Commendation for Outstanding Contribution to Bio-Industry Development, recognizing his pioneering work in peptide therapeutics and translational medicine.

2025.11

Incheon SME Grand Prize and Excellence Award

RudaCure Co., Ltd. was honored with the 2025 Incheon Small and Medium Enterprise Grand Prize and selected as an Outstanding Enterprise, highlighting our innovation in peptide drug discovery and commercialization.

2025.08

FDA Phase 2 Clinical Trial Approval for RCI001

RudaCure's dry eye disease drug candidate 'RCI001' has received U.S. FDA approval to proceed to Phase 2 clinical trials, marking a significant milestone in our journey to develop therapeutics leveraging novel TRPV1-associated regulatory mechanisms.

2025.01

Featured in The Scientist: GLP-1 Drugs & Brain Effects

Our research on GLP-1 receptor agonists and their unexplored neurological effects was featured in The Scientist. The article highlights emerging evidence of how weight-loss drugs may impact brain function beyond metabolic regulation. Read more

Join Our Team

We are always looking for passionate scientists

We are Recruiting

Open Positions

Postdoctoral Fellows • Graduate Students (Ph.D. & M.S.) • Research Scientists

We seek passionate researchers with backgrounds in:

  • Electrophysiology
  • Calcium imaging
  • Molecular biology
  • Peptide chemistry & pharmacology
  • Computational biology / AI

Why Join PRiME Lab?

  • Cutting-edge facilities & technology
  • Collaborative international research network
  • Direct translational path (lab → RudaCure → clinic)
  • Competitive salary & benefits
  • Career development support
Contact Us to Apply

Contact Us

Get in touch with PRiME Lab

Address

Lee Gil Ya Cancer and Diabetes Institute
Gachon University
155 Gaetbeol-ro, Yeonsu-gu
Incheon 21999, South Korea